Comparative Pharmacology
Head-to-head clinical analysis: AVANAFIL versus TADALAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANAFIL versus TADALAFIL.
AVANAFIL vs TADALAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing nitric oxide-mediated relaxation of smooth muscle in the corpus cavernosum, increasing cGMP levels, and promoting penile erection.
Inhibitor of phosphodiesterase type 5 (PDE5), enhancing cyclic guanosine monophosphate (cGMP)-mediated relaxation of smooth muscle in the corpus cavernosum and pulmonary vasculature.
100 mg orally once daily, taken 30-60 minutes before sexual activity. Maximum dosing frequency: once daily.
Erectile dysfunction: 10-20 mg orally as needed, 30-60 minutes before sexual activity; maximum 1 dose per day. Benign prostatic hyperplasia: 5 mg orally once daily. Pulmonary arterial hypertension: 40 mg orally once daily.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateTadalafil + Torasemide
"Tadalafil may increase the antihypertensive activities of Torasemide."
Clinical Note
moderateAvanafil + Torasemide
"Avanafil may increase the antihypertensive activities of Torasemide."
Clinical Note
moderateTadalafil + Travoprost
"Tadalafil may increase the antihypertensive activities of Travoprost."
Clinical Note
moderateAvanafil + Travoprost
"Avanafil may increase the antihypertensive activities of Travoprost."
Terminal elimination half-life approximately 6-8 hours. Clinical context: Supports once-daily dosing; steady-state reached within 5 days with no accumulation at FDA-approved dose.
Terminal elimination half-life is 17.5 hours in healthy subjects; supports once-daily dosing and prolonged effect (up to 36 hours for erectile function).
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with metabolites excreted in feces (approximately 82-90%) and urine (approximately 6-8% as unchanged drug and minor metabolites).
Primarily hepatic metabolism (CYP3A4); 36% excreted in urine (mainly metabolites), 61% in feces (mainly metabolites), <0.1% unchanged in urine.
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor